Zydus Lifesciences on Tuesday said it has received approval from the U.S. health regulator to market blood pressure lowering drug Bisoprolol Fumarate and Hydrochlorothiazide tablets in the American market.
The company has received approval from the U.S. Food and Drug Administration to market the generic medication in multiple strengths, the Ahmedabad-based drug maker said in a statement.
Bisoprolol Fumarate and hydrochlorothiazide combination is indicated to treat high blood pressure (hypertension).
The drug will be manufactured at the company's formulation manufacturing facility at Ahmedabad SEZ, the company said.
As per IQVIA MAT September 2022 data, Bisoprolol Fumarate and Hydrochlorothiazide tablets had annual sales of $27.1 million in the United States.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
